FacebookTwitterLinkedIn
cookie::
View Now

NASH Patient Access and Screening Strategies or NASH PASS: An epidemiological, multicenter, prospective screening registry for adults with nonalcoholic steatohepatitis

Linda Morrow, Julie Willard, Heidi Guthrie, Moises Hernandez, Kristin Stanley, Julia Sanchez, Carine Beysen and Marcus Hompesch

View Now

Effect of Dawn Phenomenon on Glucose Infusion Rate During Glucose Clamp Studies In Subjects with Type 1 Diabetes

Bridgette Boggess Franey, MD; Alejandra Macias Pulido, MD; Linda Morrow, MD; Marcus Hompesch, MD
Poster presented at the Diabetes Technology Meeting, North Bethesda, Maryland. 2019 Nov.

View Now

Glucose Clamp Quality Parameters Among Study Populations

Alejandra Macias Pulido, MD; Linda Morrow, MD; Gabriela Campos-Cortes, MD; Julie Willard, MD; Moises Hernandez, MD; Marcus Hompesch, MD
Poster presented at the Diabetes Technology Meeting, North Bethesda, Maryland. 2019 Nov.

View Now

Effects of efpeglenatide on weight, BMI, and waist circumference in those with obesity without diabetes stratified by baseline characteristics: subanalysis of BALANCE 205

Sorli C, Pratley R, Jacob S, Kang J, Trautmann M, Hompesch M, Han O, Stewart J, Ogbaa I, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.
View Now

Relationship between glycaemic control and weight loss with once-weekly efpeglenatide in uncontrolled type 2 diabetes: a subanalysis of EXCEED 203

Michael Trautmann, Rosenstock J, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Ogbaa I, Sorli C, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.
View Now

Efficacy of efpeglenatide in patients with obesity and prediabetes: a subanalysis of the BALANCE 205 study

Ogbaa I, Pratley R, Jacob S, Kang J, Trautmann M, Hompesch M, Han O, Stewart J, Sorli C, Yoon K Poster presented at 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), Barcelona, Spain. 2019 Sept.
View Now

Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study

Pratley, R.E.; Jacob, S; Kang, J; Trautmann, M.E.; Hompesch, M; Han, O; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K. Presentation at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

NGM313, a Novel Activator of β-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects

Depaoli, A; Phung, V; Bashir, M.R.; Morrow, L; Beysen, C; Yan, A; Ling, L; Baxter, B; Luskey, K.L.; Olefsky, J.M. Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese

Choi, J.D.; Baek, S; Kim, Y; Eun, K; Kwon, S.C.; Morrow, L; Hompesch, M; Kang, J Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205

Pratley, R.E.; Jacob, S; Kang, J; Trautmann, M.E.; Hompesch, M; Han, O; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Rosenstock, J; Morales Sr., C; Wendisch, U; Dailey III, G.E.; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Stewart, J.A.; Ogbaa, I; Sorli, C.H.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?

Dailey III, G.E.; Rosenstock, J; Morales Sr., C; Wendisch, U; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Sorli, C.H.; Ogbaa, I; Stewart, J.A.; Yoon, K Poster presented at American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA. 2019 Jun.
View Now

Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption

Powell D, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P. Presentation at the Endocrine Society Annual Meeting, New Orleans, LA. 2019 Mar 25.
View Now

Relationship Between Controlled Attenuation Parameter (CAP) and Magnetic Resonance Imaging-Derived Proton Density Fat Fraction (MRI-PDFF) in Subjects at High Risk for Nonalcoholic Fatty Liver Disease (NAFLD)

Heidi Guthrie, Natalia Castro, Carine Beysen, Linda Morrow and Marcus Hompesch
Poster presented at the NASH-TAG Conference, Park City, UT. 2019 Jan 3-5.

View Now

MEDI4166, a novel antibody-peptide fusion molecule: multiple-ascending-dose study in patients with type 2 diabetes

Carlson, G; Cook, W; Morrow, L; Petrone, M; White, N; Wang, T; Ambery, P; Hirshberg, B; Jain, M Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension

Seferovic, J.P.; Wilson, P; Carlson, K.E.; Jung, J; Wakefield, J.D.; Miller, P; Chickering, J.G.; Morrow, L; Currie, M.G.; Milne, G.T.; Profy, A.T.; Hanrahan, J.P. Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

Preclinical effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, compared with liraglutide and dulaglutide

Trautmann, M; Choi, I; Kim, J; Sorli, C Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

Investigations into tissue distribution and inhibition of food consumption with efpeglenatide

Park, Y; Choi, I; Trautmann, M; Hompesch, M; Sorli, C Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

The effect of efpeglenatide on lipid profiles and overall metabolism in patients with type 2 diabetes and obese patients without diabetes

Yoon, K; Kang, J; Choi, I; Trautmann, M; Hompesch, M; Sorli, C; Pratley, R Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

In vitro studies to evaluate the receptor kinetics of efpeglenatide versus other glucagon-like peptide-1 receptor agonists

Choi, I; Moon, M; Trautmann, M; Hompesch, M; Sorli, C Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany. 2018 Oct.
View Now

Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements

Xiaosu, M.A.; Prescilla, R.P.; Zhang, S; Linnebjerg, H; Morrow, L; Jackson, J.A.; Johnson, J; Leishman, D Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

In Vitro Studies to Evaluate the Receptor Kinetics of Efpeglenatide vs. Other Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists

Choi, I.Y.; Moon, M.J.; Trautmann, M.E.; Hompesch, M; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Park, Y.J.; Choi, I.Y.; Trautmann, M.E.; Hompesch, M; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies

Del Prato, S; Choi, I.Y.; Kang, J; Trautmann, M.E.; Yoon, K; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Preclinical Effects of Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, Compared with Liraglutide and Dulaglutide

Trautmann, M.E.; Choi, I.Y.; Kim, J.K.; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Exploring the Efficacy of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)—Evidence from Preclinical, Modeling, and Clinical Studies

Rosenstock, J; Trautmann, M.E.; Hompesch, M; Choi, I.Y.; Kang, J; Yoon, K; Sorli, C.H. Poster presented at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Fourteen-Day Study of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in Patients with Diabetes and Hypertension

Hanrahan, J.P.; Wakefield, J.D.; Wilson, P.J.; Miller, P; Chickering, J; Morrow, L; Hall, M.L.; Currie, M; Milne, G.T.; Profy, A.T. Presentation at American Diabetes Association (ADA) 78th Scientific Sessions, Orlando, FL. 2018 Jun.
View Now

Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials

Rodriguez-Araujo, G; Hernandez, M; Morrow, L; Millan, L; Martinez-Arranz, I; Hompesch, M
Poster presented at 2nd Annual NASH Summit, Boston, MA. 2018 Apr.

View Now

The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers

Hompesch, M; Grosjean, P; Morrow, L; Hijazi, Y; Ishibai, M; Teichert, L; Bergmann, K Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.
View Now

Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects

Arora, P.S.; Wong, C; Baruch, A; Chinn, L; Vaze, A; Sonoda, J; Gelzleichter, T; Chen, S; Lewin-Koh, N; Morrow, L; Boismenu, R Presentation at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.
View Now

MEDI4166, a novel antibody (PCSK9)-peptide (GLP-1) fusion molecule: single-ascending-dose study in patients with type 2 diabetes

Jain, M; Cook, W; Morrow, L; Petrone, M; Pu, W; Ambery, P; Hirshberg, B; Carlson, G Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal. 2017 Sept.

To inquire about additional poster presentations, please contact abby.devine@prosciento.com. To receive updates about new publications and poster presentations, please click here.

in cat NOT

Learn about ProSciento services for COVID-19 clinical studies in healthy subjects